Their study demonstrated that in primary bronchial epithelial cells derived from CF patients, VX-445, when combined with type 1correctors (VX-809, VX-661) and the type 2 corrector corr4a, restored approximately 60–70% of F508del CFTR function compared to non-CF cells. This evidence concerns the gene CFTR and cystic fibrosis.